ACC pipeline
What is next, and who is running it?
The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.
A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.
ClassNone selected
21 of 23 programs on this timeline
202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today
AstraZeneca 1
Registry, Dec 31, 2029
Ayala Pharmaceuticals 1
No dated milestone in 2025 to 2030
Cellestia Biotech 1
CB-103Phase 1/2
Registry, Jun 2027
Dana-Farber Cancer Institute 1
IvonescimabPhase 2
Registry, Jul 2027
Eisai (investigator studies) 1
Lenvatinib (off Label)Phase 2
Registry, Dec 2026
Elevar Therapeutics 1
RivoceranibTrials stopped
No dated milestone in 2025 to 2030
Exelixis 1
ZanzalintinibPhase 2
Registry, Apr 2029
Eye and ENT Hospital of Fudan University 1
Registry, Jun 2028
HitGen 1
HG146Phase 2
Registry, Dec 31, 2028
Memorial Sloan Kettering 1
Enfortumab VedotinPhase 2
Registry, Mar 2027
Memorial Sloan Kettering (investigator) 1
Regorafenib (off Label)Phase 2
No dated milestone in 2025 to 2030
National Cancer Centre Singapore 1
Registry, Oct 31, 2028
National Cancer Institute 1
SX-682 + DocetaxelPhase 1/2
Registry, Oct 2036
Pfizer 1
Axitinib (off Label)Phase 2
No dated milestone in 2025 to 2030
Radboud UMC; Johns Hopkins (investigators) 1
No dated milestone in 2025 to 2030
Remix Therapeutics (merging with Passage Bio) 1
REM-422Phase 1/2
ENA 2026 late-breaking oral 5LBA (updated Phase 1), Nov 19, 2026Initial Phase 2 data (company guidance), H1 2027Registry, Sep 30, 2027
Servier (registry sponsor Day One Biopharmaceuticals) 1
Registry, Feb 2027
Shanghai Ninth People's Hospital 1
ApatinibPhase 2
No dated milestone in 2025 to 2030
Trisha Wise-Draper (investigator) 1
AmivantamabPhase 2
No dated milestone in 2025 to 2030
University of Michigan 1
APG-115 (alrizomadlin)Phase 1/2
No dated milestone in 2025 to 2030
VM Oncology 1
VMD-928Phase 1/2
Registry, Dec 2027